<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01803347</url>
  </required_header>
  <id_info>
    <org_study_id>2012-001178-28</org_study_id>
    <nct_id>NCT01803347</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells</brief_title>
  <acronym>FISPAC</acronym>
  <official_title>Multicentre,Randomized,Comparative,Add-on,Into Two Parallel Groups Clinical Trial to Evaluate Efficacy and Safety of Autologous Mesenchymal Stem Cells Derived From Expanded Adipose Tissue (ASC), for Treatment of Complex Perianal Fistulizing Disease in Patients Without IBD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy of treatment of perianal fistula with mesenchymal stem cells and surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study of efficacy of adipose derived mesenchimals stem cells and surgery to treat complex
      perianal fistula
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/efficacy</measure>
    <time_frame>2014, march</time_frame>
    <description>Closure of fistulas defined as absence of suppuration and re-epithelization of the external opening and absence of collections&gt;2 cm directly related to the fistula tract treated, as measured by MRI (healing) [ Time Frame: weeks 1, 4, 12 and 16. Week 28 in patients with a second dose ]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/efficacy</measure>
    <time_frame>2015, march</time_frame>
    <description>Clinical complexity of fistula (complexity of fistula score) • Safety: Cumulative incidence of adverse effects. • Quality of life (SF-36 score) • Degree of anal incontinence (Wexner incontinence score) [ Time Frame: weeks 1, 4, 12 and 16. Week 28 in patients with a second dose ]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Anal Fistula</condition>
  <arm_group>
    <arm_group_label>ASC + fibrin glue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fibrin glue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>◦Drug: ASCs. + fibrin glue</intervention_name>
    <description>Experimental group</description>
    <arm_group_label>ASC + fibrin glue</arm_group_label>
    <other_name>Experimental Drug: ASCs + fibrin glue</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fibrin glue</intervention_name>
    <description>•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive</description>
    <arm_group_label>Fibrin glue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signature of informed consent.

          2. Complex perianal fistula cryptoglandular. Understood as a fistula in which at least
             one of the following circumstances is present:

               -  some degree of fecal incontinence associated

               -  extrasphinterics fistulas,

               -  fistulas supraresfinterianas

               -  high transsphincteric fistulas.

          3. Patients of both genders, with more that 18 years.

          4. Good overall health, according to data from the clinical history and physical
             examination.

        Exclusion Criteria:

          1. Patient diagnosed with inflammatory bowel disease.

          2. Subjects with abscess, except if a complete cleaning of the drainage area of
             collections is performed and the absence of abscess and other collections larger than
             2 cm in maximum diameter before treatment is started is confirmed.

          3. History of alcohol or substance abuse in the 6 months prior to inclusion.

          4. Malignancy, except in the case of basal cell carcinoma or squamous cell skin or a
             history of malignancy, unless they have been found in remission during the previous 5
             years.

          5. medical or psychiatric illness of any kind which, in the opinion of the investigator,
             may be a reason for exclusion from the study.

          6. Subjects with congenital or acquired immunodeficiencies. Treponema, Hepatitis B and /
             or C or tuberculosis diagnosed at the time of inclusion.

          7. Major surgery or severe trauma of the subject in the previous semester.

          8. Pregnant or lactating women.

          9. Adult women of childbearing potential not using effective contraception during the
             trial.

         10. Administration of any investigational drug at present to three months prior to
             enrollment for this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damián García-Olmo, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>59009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla-Leon</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>de la Portilla F, Alba F, García-Olmo D, Herrerías JM, González FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013 Mar;28(3):313-23. doi: 10.1007/s00384-012-1581-9. Epub 2012 Sep 29.</citation>
    <PMID>23053677</PMID>
  </results_reference>
  <results_reference>
    <citation>Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-Arranz M, Garcia-Olmo D. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis. 2012 May;27(5):595-600. doi: 10.1007/s00384-011-1350-1. Epub 2011 Nov 9.</citation>
    <PMID>22065114</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Arranz M, Gómez-Pinedo U, Hardisson D, Herreros D, Guadalajara H, García-Gómez I, García-Verdugo JM, García-Olmo D. Histopathological analysis of human specimens removed from the injection area of expanded adipose-derived stem cells. Histopathology. 2010 Jun;56(7):979-82. doi: 10.1111/j.1365-2559.2010.03573.x.</citation>
    <PMID>20636801</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.</citation>
    <PMID>19273960</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther. 2008 Sep;8(9):1417-23. doi: 10.1517/14712598.8.9.1417 . Review.</citation>
    <PMID>18694359</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005 Jul;48(7):1416-23.</citation>
    <PMID>15933795</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2013</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phase III</keyword>
  <keyword>Adipose derived stem cells</keyword>
  <keyword>Anal fistula</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Stem cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

